

# Communicable Disease Market: A BCC Research Overview

<https://marketpublishers.com/r/CAD88F5FD99EN.html>

Date: July 2019

Pages: 151

Price: US\$ 2,750.00 (Single User License)

ID: CAD88F5FD99EN

## Abstracts

### REPORT SCOPE:

The scope of this report is broad and covers therapeutics used in treatment of communicable diseases. The report highlights the current and future market potential of communicable diseases therapeutics and provides a detailed analysis of the competitive environment, regulations, epidemiology of communicable diseases, merger and acquisition, drivers, restraints, and pipeline drugs in the market. The report also covers market projections through 2024.

The report details market shares of communicable diseases based on different disease indication. Based on disease indication the market is segmented into HIV, Hepatitis B&C, Herpes Simplex Virus, Influenza, Malaria, Tuberculosis, and Others.

The market is segmented by geography into the following regions: North America, Europe, Asia-Pacific, South America, and the Middle East and Africa. The report presents detailed analyses of major countries such as the U.S., Canada, Mexico, Germany, the U.K. France, Spain, Italy, Japan, China and India. For market estimates, data is provided for 2018 as the base year, with forecasts for 2019 through 2024. Estimated values are based on product manufacturers' total revenues. Projected and forecasted revenue values are in constant U.S. dollars, unadjusted for inflation.

### REPORT INCLUDES:

23 data tables and 24 additional tables

Detailed overview of the global market for communicable diseases within the

## healthcare industry

Analyses of the global market trends, with data from 2018, estimates for 2019, and projections of compound annual growth rates (CAGRs) through 2024

Regional analysis of the communicable disease market, covering North America, Europe, Asia-Pacific, South America and Middle East & Africa

A look at the government regulations pertaining to drug developments for communicable diseases and pipeline analysis covering ongoing clinical trials and promising forthcoming therapies in late stage

Discussion of competitive landscape, mergers and acquisitions of companies to enhance their product portfolio, and future commercial marketplace

Comprehensive company profiles of major market players, including Abbott Laboratories, AbbVie Inc., GlaxoSmithKline Plc, Novartis AG and Pfizer Inc.

## Contents

### CHAPTER 1 INTRODUCTION

Study Goals and Objectives  
Reasons for Doing This Study  
Scope of Report  
Information Sources  
Methodology  
Geographic Breakdown  
Analyst's Credentials  
BCC Custom Research  
Related BCC Research Reports

### CHAPTER 2 SUMMARY AND HIGHLIGHTS

### CHAPTER 3 MARKET AND TECHNOLOGY BACKGROUND

Disease Overview  
HIV  
HIV Timeline and Milestones  
HIV Life Cycle: Treatment and Mechanism of Action  
HIV Prophylaxis  
Epidemiology  
Chlamydia  
Epidemiology  
Genital Herpes  
Epidemiology  
Gonorrhea  
Epidemiology  
Hepatitis A, B and C  
Epidemiology  
HPV  
Syphilis  
Epidemiology  
Malaria  
Incidence and Geographical Distribution  
Tuberculosis  
Incidence and Geographical Distribution

Influenza  
Incidence and Mortality  
Trichomoniasis  
Scabies  
Bacterial Vaginosis  
Candidiasis  
Chancroid (Venereal Ulcers)  
Pediculosis Pubis

## **CHAPTER 4 MARKET DYNAMICS**

Market Drivers  
Regional Awareness Program for Communicable Diseases  
Development of Novel Therapies  
Public Private Partnership  
Global Program to Counter HIV  
Increasing Prevalence of Communicable Diseases  
Market Restraints  
Social Stigma Associated with STD  
High Cost of Treatment  
Underestimating the Risk of Contracting the Disease  
Lack of Prenatal Screenings for STD

## **CHAPTER 5 MARKET BREAKDOWN BY DISEASE TYPE**

Global Market for Communicable Disease, by Disease Indication  
HIV  
Market Size and Forecast  
Market Analysis  
Hepatitis B&C  
Market Size and Forecast  
Market Analysis  
Herpes Simplex Virus  
Market Size and Forecast  
Market Analysis  
Influenza  
Market Size and Forecast  
Market Analysis  
Malaria

Market Size and Forecast

Market Analysis

Tuberculosis

Market Size and Forecast

Market Analysis

Others

Market Size and Forecast

Market Analysis

## **CHAPTER 6 MARKET BREAKDOWN BY REGION**

Global Market for Communicable Disease, by Region

North America

U.S.

Canada

Mexico

Europe

Germany

France

U.K.

Spain

Italy

Rest of Europe

Asia-Pacific

Japan

China

India

Rest of Asia-Pacific

South America

Middle East & Africa

## **CHAPTER 7 PIPELINE ANALYSIS**

Overview

Hepatitis B and Hepatitis C

Herpes Simplex Virus

HIV/AIDS

Influenza A and Influenza B

Respiratory Syncytial Virus

Malaria  
Tuberculosis  
MERS  
Hemorrhagic Fevers  
Dengue  
Ebola  
Lassa fever  
Marburg  
Yellow Fever  
Zika

## **CHAPTER 8 REGULATION AND REIMBURSEMENT**

Regulations  
U.S.  
Europe  
Japan  
China  
Pricing and Reimbursement  
U.S.  
Europe  
Japan

## **CHAPTER 9 COMPETITIVE LANDSCAPE**

Sexually Transmitted Disease Therapeutics: Global Competitor Analysis  
Influenza Therapeutics: Global Competitor Analysis

## **CHAPTER 10 COMPANY PROFILES**

ABBOTT LABORATORIES  
ABBVIE INC.  
ASTRAZENECA/MEDIMMUNE  
AUROBINDO PHARMA LTD.  
BOEHRINGER INGELHEIM PHARMACEUTICALS, INC.  
BRISTOL-MYERS SQUIBB CO.  
CIPLA INC.  
DAIICHI SANKYO  
GILEAD SCIENCES, INC.

GLAXOSMITHKLINE PLC  
JANSSEN PHARMACEUTICALS, INC.  
MERCK & CO., INC.  
MITSUBISHI TANABE PHARMA CORP.  
MYLAN LABORATORIES  
NOVARTIS AG  
PFIZER INC.  
HOFFMANN-LA ROCHE INC.  
SANOFI, SANOFI PASTEUR  
SEQIRUS, A CSL COMPANY  
VIIV HEALTHCARE

## **CHAPTER 11 APPENDIX: ACRONYMS**

## List Of Tables

### LIST OF TABLES

Summary Table: Global Communicable Disease Market, by Region, Through 2024

Table 1: Milestones in the History of HIV

Table 2: Life Cycle of HIV Therapeutics Target Points

Table 3: HIV Incidence, by Country, 2005-2016

Table 4: HIV Incidence, by Country, 2014-2017

Table 5: Chlamydia Incidence, by Country, 2012-2017

Table 6: Global HSV-1 Prevalence Aged 0-49 years, by Region, 2012

Table 7: Gonorrhea Epidemiology, by Country, 2012-2017

Table 8: Hepatitis A Incidence, by Country, 2012-2017

Table 9: Hepatitis B Incidence, by Country, 2012-2017

Table 10: Hepatitis C Incidence, by Country, 2012-2015

Table 11: Syphilis Incidence, by Country, 2013-2016

Table 12: Infectious Syphilis Incidence, by Country, 2012-2014

Table 13: Suspected Malaria Cases, by WHO Region, 2010-2015

Table 14: Confirmed Malaria Cases, by WHO Region, 2010-2015

Table 15: U.S. Impact of 2009 H1N1 Influenza, Cases and Related Hospitalizations and Deaths, by Age Group, April 2009-2010

Table 16: Trichomonas Vaginalis Diagnostic Assay, by Brand Name, Type and Manufacturer

Table 17: Bacterial Vaginosis Diagnostic Products, by Brand Name and Manufacturer

Table 18: Global Communicable Disease Market, by Disease Indication, Through 2024

Table 19: Global HIV Therapeutics Market, by Drug Class, Through 2024

Table 20: ART Therapy Coverage, by Region, 2017

Table 21: North American Estimated HBsAG Seroprevalence, 2016

Table 22: Drug for Chlamydia Treatment

Table 23: Drug for Gonorrhea Treatment

Table 24: Global Communicable Disease Market, by Region, Through 2024

Table 25: North American Communicable Disease Market, by Country, Through 2024

Table 26: European Communicable Disease Market, by Country/Region, Through 2024

Table 27: Asia-Pacific Communicable Disease Market, by Country/Region, Through 2024

Table 28: South American Estimated HBsAG Seroprevalence, by Country, 2016

Table 29: Hepatitis B and Hepatitis C Development Pipeline and Recent Launches, 2019

Table 30: Herpes Simplex Virus Development Pipeline and Recent Launches, 2019



Table 31: HIV/AIDS Development Pipeline and Recent Launches, 2019

Table 32: Influenza A and Influenza B Development Pipeline and Recent Launches, 2019

Table 33: RSV Development Pipeline and Recent Launches, 2019

Table 34: Malaria Development Pipeline and Recent Launches, 2019

Table 35: Tuberculosis Development Pipeline and Recent Launches, 2019

Table 36: MERS Development Pipeline and Recent Launches, 2019

Table 37: Dengue Development Pipeline and Recent Launches, 2019

Table 38: Ebola Development Pipeline and Recent Launches, 2019

Table 39: Lassa Fever Development Pipeline and Recent Launches, 2019

Table 40: Marburg Development Pipeline and Recent Launches, 2019

Table 41: Yellow Fever Development Pipeline and Recent Launches, 2019

Table 42: Zika Development Pipeline and Recent Launches, 2019

Table 43: Preventive Health Services for Adults Covered by Private Plans without Cost Sharing

Table 44: Preventive Health Services for Children Covered by Private Plans without Cost Sharing

Table 45: Global Market Share Analysis for Sexually Transmitted Disease Therapeutics, by Company, 2019

Table 46: Acronyms Used in This Report

## List Of Figures

### LIST OF FIGURES

Summary Figure: Global Communicable Disease Market Share, by Region, 2018

Figure 1: Types of Drug Failure Encountered During HIV Treatment

Figure 2: Global Historic and Current HIV Prevalence Trend, 2012-2016

Figure 3: Estimated HIV Regional Prevalence, 2016

Figure 4: Estimated HIV Regional Incidence, 2016

Figure 5: Global Historic and Current Chlamydia Incidence Women Trend, 2012-2014

Figure 6: Global Historic and Current Chlamydia Incidence Men Trend, 2012-2014

Figure 7: Global Historic and Current Gonorrhea Incidence Men Trend, 2012-2014

Figure 8: Global Historic and Current Gonorrhea Incidence Women Trend, 2012-2014

Figure 9: Hepatitis Timeline, 1990-2004

Figure 10: Hepatitis Timeline, 2011-2015

Figure 11: Hepatitis Timeline, 2015-2017

Figure 12: U.S. Syphilis Incidence Among Newborns, 2014-2016

Figure 13: Global Historic and Current Infectious Syphilis Incidence Men Trend, 2012-2014

Figure 14: Global Prevalence of Tuberculosis, 1990-2015

Figure 15: Global Incidence of Tuberculosis, 1990-2015

Figure 16: U.S. Funding Trend, HIV/AIDS, Viral Hepatitis, STIs, and TB, 2014-2017

Figure 17: Estimated Deaths Owing to Infectious and Parasitic Diseases, 2016

Figure 18: Global Historic and Current Gonorrhea Incidence Men Trend, 2012-2014

Figure 19: Global Communicable Disease Market, by Disease Indication, 2018-2024

Figure 20: Global HIV Market, 2018-2024

Figure 21: Global Prevalence of HIV, by Region, 2016

Figure 22: Global Incidence of HIV, by Region, 2016

Figure 23: Global Hepatitis Market, 2018-2024

Figure 24: Global Herpes Simplex Virus Market, 2018-2024

Figure 25: Global Market for HSV Therapeutics, by WHO Region, 2016-2022

Figure 26: Global Influenza Market, 2018-2024

Figure 27: Global Market for Influenza Therapeutics, by Contract Type, 2007-2017

Figure 28: Global Malaria Market, 2018-2024

Figure 29: Global Tuberculosis Market, 2018-2024

Figure 30: Global Others Market, 2018-2024

Figure 31: Global Communicable Disease Market Share, by Region, 2018

Figure 32: North American Communicable Disease Market, 2018-2024

Figure 33: North American Communicable Disease Market Share, by Country, 2018

- Figure 34: U.S. Communicable Disease Market, 2018-2024
- Figure 35: Canadian Communicable Disease Market, 2018-2024
- Figure 36: Mexican Communicable Disease Market, 2018-2024
- Figure 37: European Communicable Disease Market Share, by Country/Region, 2018
- Figure 38: German Communicable Disease Market, 2018-2024
- Figure 39: French Communicable Disease Market, 2018-2024
- Figure 40: French Historic and Current Chlamydia Incidence Trend, 2011-2015
- Figure 41: French Historic and Current Gonorrhea Incidence Trend, 2011-2015
- Figure 42: U.K. Communicable Disease Market, 2018-2024
- Figure 43: Spanish Communicable Disease Market, 2018-2024
- Figure 44: Italian Communicable Disease Market, 2018-2024
- Figure 45: Rest of European Communicable Disease Market, 2018-2024
- Figure 46: Asia-Pacific Communicable Disease Market Share, by Country/Region, 2018
- Figure 47: Japanese Communicable Disease Market, 2018-2024
- Figure 48: Japanese Historic and Current HIV/AIDS Infections Incidence, 2001-2016
- Figure 49: Chinese Communicable Disease Market, 2018-2024
- Figure 50: Indian Communicable Disease Market, 2018-2024
- Figure 51: Rest of Asia-Pacific Communicable Disease Market, 2018-2024
- Figure 52: South American Communicable Disease Market, 2018-2024
- Figure 53: Middle East and African Communicable Disease Market, 2018-2024
- Figure 54: Global Influenza Therapeutics Market Share, by Manufacturer, 2018
- Figure 55: Global Competitor Market Analysis for Influenza Therapeutics, 2018

## I would like to order

Product name: Communicable Disease Market: A BCC Research Overview

Product link: <https://marketpublishers.com/r/CAD88F5FD99EN.html>

Price: US\$ 2,750.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

[info@marketpublishers.com](mailto:info@marketpublishers.com)

## Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/CAD88F5FD99EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:  
Last name:  
Email:  
Company:  
Address:  
City:  
Zip code:  
Country:  
Tel:  
Fax:  
Your message:

**\*\*All fields are required**

Customer signature \_\_\_\_\_

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970